anaemia
Conditions
Interventions
Test group:intravenous isomaltose iron combined with erythropoietin and tranexamic acid
Control group:conventional treatment
Sponsors
Peking University People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients aged 18 and above with primary malignant bone tumors and bone metastases who plan to undergo open surgery for the sacrum, pelvis, and spine; 2.5 ± 2 days before surgery, hemoglobin<130g/L, or iron deficiency (TSAT<20%); 3.Patients are able to understand the research content and sign informed consent forms.
Exclusion criteria
Exclusion criteria: 1. Ferritin > 800 ng/ml or hemoglobin < 70g/L; 2. Expected survival time is less than six months; 3. Women who are pregnant, breastfeeding or planning to become pregnant; 4. Known allergic reactions to other iron agents; 5. Severe myelosuppressive events (4th degree myelosuppression) 4 weeks before enrollment; 6. Decompensated period of liver disease; 7. Patients with acute infection; 8. Chronic kidney disease stage 3-5; 9. Patients who received oral iron, intravenous iron, EPO, or blood transfusion therapy within 1 month before the start of the study; 10. Other conditions that the investigator considers unsuitable for participating in this study, such as deafness, Parkinson's disease, communication disorders, etc.; 11. Participated in other clinical trials within three months before participating in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemoglobin level 21 days after surgery; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood transfusion rate and volume within 21 days after surgery;Hemoglobin levels 7 and 14 days after surgery;Proportion of iron deficiency on postoperative days 7, 14, and 21; | — |
Countries
China
Contacts
Public ContactTang Xiaodong
Peking University People's Hospital
Outcome results
None listed